Sumitomo Dainippon Pharma Co Ltd (4506)

Currency in JPY
1,105.0
+68.0(+6.56%)
Closed·
4506 Scorecard
Full Analysis
Has a perfect Piotroski Score of 9
Earnings results expected in 8 days
Fair Value
Day's Range
1,050.01,106.0
52 wk Range
401.01,122.0
Key Statistics
Bid/Ask
1,104.00 / 1,105.00
Prev. Close
1,037
Open
1,051
Day's Range
1,050-1,106
52 wk Range
401-1,122
Volume
8.09M
Average Volume (3m)
12.29M
1-Year Change
157.62%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4506 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
797.5
Downside
-27.83%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Sumitomo Dainippon Pharma Co Ltd Company Profile

Sumitomo Pharma Co., Ltd. engages in manufacture, and purchase and sale of pharmaceutical products for medical treatment in Japan, North America, and Asia. The company offers therapeutic agents for parkinson’s disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. It also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. Further, the company offers veterinary drugs, medical devices, etc. It has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Employees
3832
Market
Japan

Compare 4506 to Peers and Sector

Metrics to compare
4506
Peers
Sector
Relationship
P/E Ratio
18.6x13.2x−0.5x
PEG Ratio
0.170.070.00
Price/Book
2.6x1.0x2.6x
Price / LTM Sales
1.1x1.5x3.2x
Upside (Analyst Target)
−34.4%1.1%42.7%
Fair Value Upside
Unlock7.4%5.8%Unlock

Analyst Ratings

2 Buy
3 Hold
3 Sell
Ratings:
8 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 797.5
(-27.83% Downside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
6.08 / -12.55
Revenue / Forecast
105.65B / 88.33B
EPS Revisions
Last 90 days

4506 Income Statement

People Also Watch

15,545.0
7013
-3.66%
28,020.0
8035
+1.95%
3,998.0
6701
+0.23%
10,675.0
7012
+3.09%

FAQ

What Stock Exchange Does Sumitomo Dainippon Pharma Trade On?

Sumitomo Dainippon Pharma is listed and trades on the Tokyo Stock Exchange stock exchange.

What Is the Stock Symbol for Sumitomo Dainippon Pharma?

The stock symbol for Sumitomo Dainippon Pharma is "4506."

What Is the Sumitomo Dainippon Pharma Market Cap?

As of today, Sumitomo Dainippon Pharma market cap is 438.61B.

What Is Sumitomo Dainippon Pharma's Earnings Per Share (TTM)?

The Sumitomo Dainippon Pharma EPS (TTM) is 59.49.

When Is the Next Sumitomo Dainippon Pharma Earnings Date?

Sumitomo Dainippon Pharma will release its next earnings report on 30 Jul 2025.

From a Technical Analysis Perspective, Is 4506 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Sumitomo Dainippon Pharma Stock Split?

Sumitomo Dainippon Pharma has split 0 times.

How Many Employees Does Sumitomo Dainippon Pharma Have?

Sumitomo Dainippon Pharma has 3832 employees.

What is the current trading status of Sumitomo Dainippon Pharma (4506)?

As of 23 Jul 2025, Sumitomo Dainippon Pharma (4506) is trading at a price of 1,105.00, with a previous close of 1,037.00. The stock has fluctuated within a day range of 1,050.00 to 1,106.00, while its 52-week range spans from 401.00 to 1,122.00.

What Is Sumitomo Dainippon Pharma (4506) Price Target According to Analysts?

The average 12-month price target for Sumitomo Dainippon Pharma is JPY797.5, with a high estimate of JPY1300 and a low estimate of JPY430. 2 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Neutral. The stock has an -27.83% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.